Rapport Therapeutics, Inc. RAPP Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -28.3%-0.1pp | -28.2%-4.8pp | -23.4%+6.0pp | -29.4%— | —— | |
| Return on assets | -26.8%+0.1pp | -26.9%-4.4pp | -22.6%+5.4pp | -28%— | —— | |
| Return on invested capital | -38.2%-2.1pp | -36.1%+3.4pp | -39.5%+5.8pp | -45.3%— | —— | |
| Liquidity | ||||||
| Current ratio | 27.1×+0.9× | 26.2×-10.2× | 36.4×+13.6× | 22.7×-8.3× | 31×-4.3× | |
| Quick ratio | 27.1×+0.9× | 26.2×-10.2× | 36.4×+13.6× | 22.7×-8.3× | 31×-4.3× | |
| Cash ratio | 4.4×+1.6× | 2.8×-14.8× | 17.6×+12.9× | 4.6×-1.5× | 6.1×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $9.98-19.8% | $12.45-7.7% | $13.49+81.4% | $7.43-8.3% | $8.11-45.0% | |
| Valuation | ||||||
| Market capitalization | $1.5B+3.4% | $1.45B+5.6% | $1.37B+203% | $451.84M+23.4% | $366.06M-43.6% | |
| Enterprise value | $1.43B+1.7% | $1.4B+24.3% | $1.13B+177% | $408.64M+29.2% | $316.3M-46.7% | |
| Price / book | 3.2×+0.2× | 3×+0.3× | 2.7×+1.0× | 1.7×+0.4× | 1.3×-0.8× | |
| Free cash flow yield | -5.4%+0.7pp | -6.1%-0.4pp | -5.7%+11.3pp | -17%+1.9pp | -18.9%-8.5pp | |
| Earnings yield | -7.2%+0.5pp | -7.7%-0.6pp | -7.1%+12.4pp | -19.5%+2.2pp | -21.8%-9.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rapport Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.